Silo Pharma Announces Closing of $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
July 22, 2024 16:45 ET
|
Silo Pharma, Inc.
SARASOTA, FL, July 22, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations...
Silo Pharma Announces $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
July 19, 2024 08:01 ET
|
Silo Pharma, Inc.
SARASOTA, FL, July 19, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations...
Silo Pharma and Resyca BV Partner on Device and CMC Development for Intranasal PTSD Drug SPC-15
July 18, 2024 08:25 ET
|
Silo Pharma, Inc.
Nose-to-Brain Drug Delivery Shows Promising Patient Safety and Therapeutic Benefit The Device and CMC Development Master Plan is designed to support IND-enabling studies SARASOTA, FL, July 18,...
Silo Pharma Secures Exclusive Global License for Alzheimer's Therapeutic
July 16, 2024 06:30 ET
|
Silo Pharma, Inc.
Agreement enhances Company’s intellectual property portfolio SARASOTA, FL, July 16, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage...
Silo Pharma Announces Exclusive, Global License for Lead Candidate SPC-15 Targeting PTSD and Stress-Induced Anxiety Disorders
July 08, 2024 08:45 ET
|
Silo Pharma, Inc.
Extensive Issued and Pending IP Patent Applications Acquired with License Agreement SARASOTA, FL, July 08, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a...
Silo Pharma Partners with AmplifyBio to Advance SPC-15 for PTSD and Anxiety
June 26, 2024 08:50 ET
|
Silo Pharma, Inc.
Amplify Bio to complete GLP study of SPC-15 Novel Intranasal Therapeutic Silo study advances SPC-15 towards first-in-human trial SARASOTA, FL, June 26, 2024 (GLOBE NEWSWIRE) -- Silo...
Silo Pharma Announces Successful Production of its SP-26 Ketamine Implant for Fibromyalgia
June 07, 2024 08:18 ET
|
Silo Pharma, Inc.
Analytical testing has confirmed optimal formulation for upcoming studies SARASOTA, FL, June 07, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental...
Silo Pharma Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
June 06, 2024 16:50 ET
|
Silo Pharma, Inc.
SARASOTA, FL, June 06, 2024 (GLOBE NEWSWIRE) -- SARASOTA, FL, June 6, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical...
Silo Pharma Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
June 05, 2024 08:00 ET
|
Silo Pharma, Inc.
SARASOTA, FL, June 05, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations...
Silo Pharma Submits Pre-Investigational New Drug Application to FDA for SPC-15 as a Treatment for PTSD and Anxiety
June 04, 2024 08:41 ET
|
Silo Pharma, Inc.
Clinical roadmap unveiled for novel and proprietary intranasal PTSD treatment SARASOTA, FL, June 04, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a...